News

Bioengineered, Sirolimus-Eluting Stent Found ‘Safe,’ and ‘Effective’


 

FROM TRANSCATHETER CARDIOVASCULAR THERAPEUTICS 2011

Dr. Haude reported that he receives research or grant support from OrbusNeich and Biotronik and consultant fees and honoraria from Medtronic, Abbott Vascular, and Volcano Corp. Dr. Hodgson reported that he receives research or grant support from Boston Scientific, Volcano Corp., and St. Jude Medical, and that he is a consultant to, is a speaker for, or receives honoraria from Volcano Corp. The trial was sponsored by OrbusNeich.

Pages

Recommended Reading

Low CV Event Rate Prompts Closure of Prasugrel Trial
MDedge Cardiology
Bleeding Events Higher With Antiplatelet Nonadherence
MDedge Cardiology
Formula Calculates Need for Heart Catheterization in SSc
MDedge Cardiology
Transfemoral TAVR Edges Surgery on Quality of Life Factors
MDedge Cardiology
TAVI's Mortality Benefit Sustained at 2 Years in PARTNER
MDedge Cardiology
Radial Access for Angioplasty Slashes Morbidity, Mortality
MDedge Cardiology
Drug-Eluting Balloon, Bare Metal Stent Combo Disappoints in STEMI
MDedge Cardiology
Zotarolimus-, Everolimus-Eluting Stents Found Equally Safe, Effective
MDedge Cardiology
Thin, Bioabsorbable Polymer Stent Promising in Early Trial
MDedge Cardiology
Drug-Eluting Balloon Angioplasty Treats In-Stent Restenosis
MDedge Cardiology